Maraciclatide
Alternative Names: 99mTc-maraciclatide; 99mTc-NC100692; GE-078; NC-100692; Tc-99m-NC100692; Tc99m-Maraciclatide; TcNC100692Latest Information Update: 01 Aug 2024
Price :
$50 *
At a glance
- Originator GE Healthcare
- Developer GE Healthcare; SERAC Healthcare
- Class Cyclic peptides; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cardiovascular disorders; Interstitial lung diseases
- Clinical Phase Unknown Endometriosis; Inflammation
- No development reported Breast cancer